ERs that explain why ERRγ does not bind estradiol or raloxifene and will help to design new selective antagonists.
INTRODUCTION
The estrogen-related receptors ERRα, ERRβ, and ERRγ (NR3B1, 2, 3) (1) form a subfamily of orphan nuclear receptors that share significant amino acid homology with the estrogen receptors ERα and ERβ [NR3A1, 2] (2, 3). Due to the high conservation in the DNA-binding domain (DBD) $ , ERRs and ERs have overlapping DNA binding selectivity (4) (5) (6) and accordingly may co-regulate target genes in tissues in which they are co-expressed. ERR subfamily members have for example been shown to modulate the expression of ER target genes in bone (7, 8) or breast tissue (9, 10) . Importantly, over-expression of ERRα and ERRγ in samples from breast cancer patients correlates with unfavourable and favourable biomarkers, respectively (11) . Therefore, these receptors might serve as prognostic markers themselves or even be targets for endocrine therapy in human breast cancer.
Despite their significant homology with ERs in the ligand-binding domain (LBD), SERM raloxifene (RAL) does not bind to ERRs (23) (summarized in Table 1 ). The activity of ERRα is also antagonized by the organochlorine pesticides chlordane and toxaphene (24) , but binding of these substances to ERRα remains unclear (21). In contradiction to structure-based predictions (12) , a recent study identified flavone and isoflavone phytoestrogens as ERR agonists (25) , although binding of these substances to the receptors has not been demonstrated.
Nuclear receptor LBDs adopt a canonical antiparallel α-helical sandwich fold generally composed of 12 α-helices (H1 to H12) and a small β-sheet (26, 27) . Agonist ligands trigger the LBD activation function (termed AF2) by stabilizing a defined conformation, in which H12 packs against the LBD body and together with H3 and H4 generates a hydrophobic coactivator binding surface. Coactivators typically bind via LXXLL sequence motifs (L denotes leucine and X any amino acid) that form amphipatic α-helices. Antagonist ligands interfere with the formation of an active LBD conformation and coactivator recruitment. In most documented cases AF2 antagonism is based on sterical interference between a bulky ligand extension protruding from the LBP and H12 in the agonist position, as exemplified by the ERα LBD bound to RAL or 4-OHT (28, 29) or the ERβ LBD complexed with ICI 164,384 (ICI) (30) . Alternatively, 'small' antagonists without bulky extension can destabilize the active LBD conformation by promoting non-productive interactions between H12 and the LBD body, as exemplified by the action of 5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (THC; R,R enantiomer) on ERβ (31) .
In crystallographic and recent fluorescence studies it has been attempted to more precisely correlate the conformation of the antagonist-bound ER LBD with the distinct biological activities elicited by SERMs (RAL, 4-OHT) or full ER antagonists (ICI compounds) in vivo (28) (29) (30) 32) . In the crystallized complexes of the ERα LBD with RAL or 4-OHT a partial unfolding of the C-terminal end of H11 and structural adaptations of the by guest on September 1, 2017 http://www.jbc.org/ Downloaded from H11/H12 loop were observed, allowing H12 to bind to the coactivator groove (28, 29) . In contrast, in the ERβ LBD/ICI complex H12 is not visible due to high mobility, since the terminal amide moiety of the ligand sterically precludes its packing against the coactivator groove (30). In turn, a high H12 mobility appears to result in an increased cellular ER turnover, accounting in part for the full antagonist activity of ICI compounds (30, 33) .
Fluorescence studies confirmed a partial unfolding of the C-terminus of H11 in ERα LBD/antagonist complexes in solution (32) . Interestingly, full antagonists seem to have a lower H11 unfolding potential than SERMs, and subtle differences were observed between the spectroscopic signatures of RAL and 4-OHT.
In contrast to ERs, nothing is known about ligand-induced conformational changes of ERR LBDs. Here we report the crystal structures of the ERRγ LBD/DES complex (at 2. The data were integrated and scaled using the HKL2000 package (34) .
Structure determination, refinement, and comparison
The crystal structures of the ERRγ LBD/DES and the ERRγ LBD/4-OHT complexes were solved by molecular replacement with AMoRe (35) using the C-terminally deleted ERRγ LBD homodimer (amino acids 235-440) (12) as search model. The structures were refined at the indicated resolution (Table 2 ) using CNS (36) and programs of the CCP4 package (37) (38) (39) (40) . Manual adjustments and rebuilding of the models were performed using the program 'O' (41) . The final models were validated with PROCHECK (42) . Data collection and structure refinement statistics are summarized in Some changes of the main chain include adaptations of the H1-H3 loop, which mainly result from crystal packing. In contrast, important structural perturbations of the main chain due to 4-OHT or DES binding affect the C-terminus of H11, the H11/H12 loop, and H12 (Table 3) . cleft in a roughly similar manner as L540, the corresponding residue in ERα (Fig. 4B) .
Packing of the N-terminal portion of the ERRγ H12 against the coactivator cleft of a neighbouring molecule, however, is precluded by the presence of the cholic acid molecule and determined by the distinct conformations of the H11/H12 loop in both ERRγ subunits.
Consequently, M446 of ERRγ does not form an interaction equivalent to that of the corresponding L536 in ERα.
DISCUSSION

Mechanism of ERRγ deactivation
In this study we compare the crystal structures of the ERRγ LBD bound to the antagonists 
A 'fortuitous' cholic acid molecule bound at the surface of the ERRγ LBD
Unexpectedly, in crystal form 1 of the ERRγ LBD/4-OHT complex, cholic acid (or a closely related bile acid) was co-crystallized. One possible explanation for the presence of cholic acid is that the molecule has been co-purified from the E. coli expression host, since bacteria present in the human colon are known to be involved in the metabolism of bile acids that escape the enterohepatic circulation (between the liver, gallbladder, and intestines) (47) . Currently, we do not see any physiological relevance for the observed association of cholic acid with the ERRγ LBD. Although ERRγ seems to be expressed at low levels in the small intestine and the liver (13, (49) (50) (51) , the binding position of the bile acid at the ERRγ surface is clearly determined by the crystal packing and only compatible with an antagonist, but not an agonist LBD conformation. It therefore also remains unclear how cholic acid was 'fortuitously' co-purified with the ERRγ apo-LBD.
Ligand binding selectivity of ERRs
ERRs have been shown to bind DES (all ERRs) and 4-OHT (ERRβ and ERRγ), but not E2 or RAL (21-23). The comparison of the DES and 4-OHT complexes of the ERRγ and the ERα
LBDs reveals small but significant differences in the architecture of the LBP that explain 
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